Harvard Catalyst Profiles

Contact, publication, and social network information about Harvard faculty and fellows.

Tracy Todd Batchelor, M.D.

Co-Author

This page shows the publications co-authored by Tracy Batchelor and Ovidiu Andronesi.
Connection Strength

3.454
  1. Pharmacodynamics of mutant-IDH1 inhibitors in glioma patients probed by in vivo 3D MRS imaging of 2-hydroxyglutarate. Nat Commun. 2018 04 16; 9(1):1474.
    View in: PubMed
    Score: 0.757
  2. Early changes in glioblastoma metabolism measured by MR spectroscopic imaging during combination of anti-angiogenic cediranib and chemoradiation therapy are associated with survival. NPJ Precis Oncol. 2017; 1.
    View in: PubMed
    Score: 0.714
  3. In Vivo Absolute Metabolite Quantification Using a Multiplexed ERETIC-RX Array Coil for Whole-Brain MR Spectroscopic Imaging. J Magn Reson Imaging. 2021 Dec 27.
    View in: PubMed
    Score: 0.244
  4. Improving D-2-hydroxyglutarate MR spectroscopic imaging in mutant isocitrate dehydrogenase glioma patients with multiplexed RF-receive/B0 -shim array coils at 3?T. NMR Biomed. 2022 01; 35(1):e4621.
    View in: PubMed
    Score: 0.241
  5. An integrated RF-receive/B0-shim array coil boosts performance of whole-brain MR spectroscopic imaging at 7 T. Sci Rep. 2020 09 14; 10(1):15029.
    View in: PubMed
    Score: 0.224
  6. Super-Resolution Whole-Brain 3D MR Spectroscopic Imaging for Mapping D-2-Hydroxyglutarate and Tumor Metabolism in Isocitrate Dehydrogenase 1-mutated Human Gliomas. Radiology. 2020 03; 294(3):589-597.
    View in: PubMed
    Score: 0.213
  7. Volumetric relationship between 2-hydroxyglutarate and FLAIR hyperintensity has potential implications for radiotherapy planning of mutant IDH glioma patients. Neuro Oncol. 2016 11; 18(11):1569-1578.
    View in: PubMed
    Score: 0.167
  8. Treatment Response Assessment in IDH-Mutant Glioma Patients by Noninvasive 3D Functional Spectroscopic Mapping of 2-Hydroxyglutarate. Clin Cancer Res. 2016 Apr 01; 22(7):1632-41.
    View in: PubMed
    Score: 0.160
  9. Sherry apple resident travel scholarship 194 assessment of treatment response in isocitrate dehydrogenase-mutant gliomas by quantification of 2-hydroxyglutarate with in vivo 3-dimensional magnetic resonance spectroscopy. Neurosurgery. 2014 Aug; 61 Suppl 1:224.
    View in: PubMed
    Score: 0.146
  10. Detection of oncogenic IDH1 mutations using magnetic resonance spectroscopy of 2-hydroxyglutarate. J Clin Invest. 2013 Sep; 123(9):3659-63.
    View in: PubMed
    Score: 0.137
  11. Detection of 2-hydroxyglutarate in IDH-mutated glioma patients by in vivo spectral-editing and 2D correlation magnetic resonance spectroscopy. Sci Transl Med. 2012 Jan 11; 4(116):116ra4.
    View in: PubMed
    Score: 0.123
  12. Myo-Inositol Levels Measured with MR Spectroscopy Can Help Predict Failure of Antiangiogenic Treatment in Recurrent Glioblastoma. Radiology. 2022 02; 302(2):410-418.
    View in: PubMed
    Score: 0.061
  13. Consensus recommendations for MRI and PET imaging of primary central nervous system lymphoma: guideline statement from the International Primary CNS Lymphoma Collaborative Group (IPCG). Neuro Oncol. 2021 07 01; 23(7):1056-1071.
    View in: PubMed
    Score: 0.059
  14. MR spectroscopic imaging predicts early response to anti-angiogenic therapy in recurrent glioblastoma. Neurooncol Adv. 2021 Jan-Dec; 3(1):vdab060.
    View in: PubMed
    Score: 0.058
  15. Bone marrow drives central nervous system regeneration after radiation injury. J Clin Invest. 2018 06 01; 128(6):2651.
    View in: PubMed
    Score: 0.048
  16. Bone marrow drives central nervous system regeneration after radiation injury. J Clin Invest. 2018 01 02; 128(1):281-293.
    View in: PubMed
    Score: 0.046
  17. Serial magnetic resonance spectroscopy reveals a direct metabolic effect of cediranib in glioblastoma. Cancer Res. 2011 Jun 01; 71(11):3745-52.
    View in: PubMed
    Score: 0.029
  18. Glioblastoma recurrence after cediranib therapy in patients: lack of "rebound" revascularization as mode of escape. Cancer Res. 2011 Jan 01; 71(1):19-28.
    View in: PubMed
    Score: 0.029
Connection Strength
The connection strength for co-authors is the sum of the scores for each of their shared publications.

Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.
Funded by the NIH National Center for Advancing Translational Sciences through its Clinical and Translational Science Awards Program, grant number UL1TR002541.